Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06254664 · ClinicalTrials.gov registry record · Phase 1
Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device
A Phase 1 study, sponsored by Xiromed.
- Completed
- Registry status
- Phase 1
- Development phase
- 116
- Enrollment target
NCT06254664 is a Phase 1 study that has completed, run by Xiromed. The registered enrollment target is 116 participants.
The verdict
NCT06254664, a Phase 1 study, has completed, sponsored by Xiromed.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 116 participants
- Enrollment target
Study Summary
An Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule, Inhaler Device. Zephir inhaler robustness will be assessed by in vitro testing of the Zephir inhaler after 12 weeks of patient use
Interventions
- DRUG Tiotropium 18 µg inhalation powder, hard capsule
- DEVICE Zephir inhaler
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2023-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06254664
The ClinicalTrials.gov registry entry for NCT06254664 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xiromed, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tiotropium 18 µg inhalation powder, hard capsule is the first listed.
NCT06254664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06254664 about?
NCT06254664 is a clinical study titled "Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device". An Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule, Inhaler Device. Zephir inhaler robustness will be assessed by in vitro testing of the Zephir inhaler after 12 weeks of patient use
What is the current status of trial NCT06254664?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 116 participants. The study started on 2022-10-03. Estimated completion is 2023-10-27.
What interventions are being tested in trial NCT06254664?
The interventions under investigation include: Tiotropium 18 µg inhalation powder, hard capsule (DRUG), Zephir inhaler (DEVICE).
Who is sponsoring clinical trial NCT06254664?
This trial is sponsored by Xiromed, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.